| Patents for A61K 39 - Medicinal preparations containing antigens or antibodies (182,248) |
|---|
| 02/21/2013 | WO2013024097A1 Combination therapy with an anti - cd19 antibody and a nitrogen mustard |
| 02/21/2013 | WO2013024095A1 Combination therapy with an anti - cd19 antibody and a purine analog |
| 02/21/2013 | WO2013023557A1 Humanized monoclone antibody of macrophage inhibition factor 1 and use thereof |
| 02/21/2013 | WO2013023376A1 Microvesicle membrane protein and application thereof |
| 02/21/2013 | WO2013023362A1 Cytomegalovirus human immunoglobulin for intravenous injection, and preparation method therefor |
| 02/21/2013 | WO2013023251A1 Soluble polypeptides |
| 02/21/2013 | WO2013006050A9 Peptides inducing or enhancing an immune response against prostate-specific membrane protein (psma) |
| 02/21/2013 | WO2013002485A3 Pharmaceutical composition for preventing and treating kidney disorders, containing inhibitor for phosphorylation of taz tyrosine as active ingredient for activation of nfat5/tonebp |
| 02/21/2013 | WO2012177658A3 Methods of treating and preventing staphylococcus aureus infections and associated conditions |
| 02/21/2013 | WO2012158624A3 Inhibitors of mitochondrial fission and methods of use thereof |
| 02/21/2013 | WO2012154944A9 Methods of treating autophagy-associated disorders and related pharmaceutical compositions, diagnostics, screening techniques and kits |
| 02/21/2013 | WO2012038565A3 PROTEINS OF THE CRY FAMILY AS MARKERS FOR DETERMINING THE RISK OF DEVELOPING AN α-SYNUCLEINOPATHY OR DETERMINING SAID DISEASE |
| 02/21/2013 | WO2012009576A9 Prevention and treatment of pain using monoclonal antibodies and antibody fragments to lysophosphatidic acid |
| 02/21/2013 | WO2011160119A8 Anti-gd2 antibodies |
| 02/21/2013 | WO2011116954A8 Prophylaxis of colorectal and gastrointestinal cancer |
| 02/21/2013 | US20130046257 Methods of using agents that modulate claudin expression |
| 02/21/2013 | US20130045267 Methods of using agents that modulate claudin expression |
| 02/21/2013 | US20130045243 NANOGENOMICS FOR MEDICINE: siRNA ENGINEERING |
| 02/21/2013 | US20130045237 Combination pharmaceutical composition and methods of treating and preventing the infectious diseases |
| 02/21/2013 | US20130045235 Autologous biological cancer vaccine |
| 02/21/2013 | US20130045234 Neutralizing factors as vaccine adjuvants |
| 02/21/2013 | US20130045233 Novel Allergen |
| 02/21/2013 | US20130045232 Mucosal vaccines |
| 02/21/2013 | US20130045231 Immunogenic composition |
| 02/21/2013 | US20130045230 Composition containing hcmv particles |
| 02/21/2013 | US20130045229 Anti-Viral Compounds |
| 02/21/2013 | US20130045228 Vaccine for protection against lawsonia intracellularis |
| 02/21/2013 | US20130045225 Synthetic Antigen Based on the Ligand Domain of the Plasmodium vivax Duffy Binding Protein |
| 02/21/2013 | US20130045224 Immunostimulatory compositions and methods of use thereof |
| 02/21/2013 | US20130045223 Methods and compositions to protect aquatic invertebrates from disease |
| 02/21/2013 | US20130045222 Compositions and methods for enhancing immune responses to vaccines |
| 02/21/2013 | US20130045220 Microvesicle Membrane Protein And Application Thereof |
| 02/21/2013 | US20130045219 Binding proteins, including antibodies, antibody derivatives and antibody fragments, that specifically bind cd154 and uses thereof |
| 02/21/2013 | US20130045218 Fc receptor binding proteins |
| 02/21/2013 | US20130045217 Lipidomic biomarkers for atherosclerosis and cardiovascular disease |
| 02/21/2013 | US20130045216 Method for Treating Amyloid Disease |
| 02/21/2013 | US20130045215 Growth hormone receptor deficiency causes a major reduction in pro-aging signaling, cancer and diabetes in humans |
| 02/21/2013 | US20130045214 P53 modulator and cancer target |
| 02/21/2013 | US20130045213 Antibody therapy for modulating function of intestinal receptors and methods of treating diabetes and obesity |
| 02/21/2013 | US20130045212 Biological Materials and Uses Thereof |
| 02/21/2013 | US20130045211 Methods and compositions for enhanced immunological therapy and targeting of gram-positive bacteria |
| 02/21/2013 | US20130045210 Pharmaceutical composition for treating and/or preventing cancer |
| 02/21/2013 | US20130045209 WNT-Binding Agents and Uses Thereof |
| 02/21/2013 | US20130045208 Methods for the Treatment of an Infectious Bacterial Disease with an Anti-Lactone or Lactone Derived Signal Molecules Antibody |
| 02/21/2013 | US20130045207 Antibody against serotype g lipopolysaccharide of pseudomonas aeruginosa |
| 02/21/2013 | US20130045206 Antibodies directed against the transferrin receptor and uses thereof for immunotherapy of iron-dependent tumours |
| 02/21/2013 | US20130045205 Methods and Compositions Related to Glycoprotein-Immunoglobulin Fusions |
| 02/21/2013 | US20130045204 Fluorinated bisphenol ether compounds and methods for their use |
| 02/21/2013 | US20130045203 Uses of Noscapine and Derivatives in Subjects Diagnosed with FAP |
| 02/21/2013 | US20130045202 Anti-pd-l1 antibodies and articles of manufacture |
| 02/21/2013 | US20130045201 Methods of using anti-pd-l1 antibodies and their use to enhance t-cell function to treat tumor immunity |
| 02/21/2013 | US20130045200 Methods of using anti-pd-l1 antibodies and their use to treat infection resulting from t-cell dysfunction |
| 02/21/2013 | US20130045199 Antibody Preparations |
| 02/21/2013 | US20130045198 Genetic polymorphisms associated with venous thrombosis, methods of detection and uses thereof |
| 02/21/2013 | US20130045181 Methods and Compositions for Chlamydial Antigens for Diagnosis and Treatment of Chlamydial Infection and Disease |
| 02/21/2013 | US20130045180 Vaccines, immunotherapeutics and methods for using the same |
| 02/21/2013 | US20130045162 Delivery system for specifically targeting cancer cells and method of use thereof |
| 02/21/2013 | US20130045160 Magnetic Nano-Composite for Contrast Agent, Intelligent Contrast Agent, Drug Delivery Agent for Simultaneous Diagnosis and Treatment, and Separation Agent for Target Substance |
| 02/21/2013 | CA2846240A1 Antibodies that bind integrin alpha-v beta-8 |
| 02/21/2013 | CA2845583A1 Compositions and methods for prevention of escape mutation in the treatment of her2/neu over-expressing tumors |
| 02/21/2013 | CA2845545A1 Molecular mimic mucosal aids vaccine |
| 02/21/2013 | CA2845536A1 Anti-b7-h4 antibodies and their uses |
| 02/21/2013 | CA2845391A1 Soluble polypeptides |
| 02/21/2013 | CA2845259A1 Compositions and methods related to antibodies to staphylococcal protein a |
| 02/21/2013 | CA2845040A1 Influenza h5 vaccines |
| 02/21/2013 | CA2844674A1 Methods of treating hematological proliferative disorders by targeting epha3 expressed on aberrant vasculature in bone marrow |
| 02/21/2013 | CA2844289A1 Anti-fzd10 monoclonal antibodies and methods for their use |
| 02/21/2013 | CA2844126A1 Microvesicle membrane protein and application thereof |
| 02/21/2013 | CA2842375A1 Neuregulin antibodies and uses thereof |
| 02/21/2013 | CA2841875A1 Combination therapy with an anti - cd19 antibody and a nitrogen mustard |
| 02/21/2013 | CA2841738A1 Combination therapy with an anti - cd19 antibody and a purine analog |
| 02/20/2013 | EP2559762A1 Novel anti-hsp90 monoclonal antibody |
| 02/20/2013 | EP2559706A1 Monoclonal antibodies that bind to hGM-CSF and medical compositions comprising same |
| 02/20/2013 | EP2559705A2 Anti-activin a antibodies and uses thereof |
| 02/20/2013 | EP2559440A2 A microvesicle membrane protein and application thereof |
| 02/20/2013 | EP2558581A1 Poxvirus expression system |
| 02/20/2013 | EP2558500A1 Proteins that bind pi16 and uses thereof |
| 02/20/2013 | EP2558498A2 Antibodies that bind human cd27 and uses thereof |
| 02/20/2013 | EP2558497A2 Human fgf receptor and beta-klotho binding proteins |
| 02/20/2013 | EP2558496A1 Anti-polyubiquitin antibodies and methods of use |
| 02/20/2013 | EP2558493A2 Antibodies for the treatment of clostridium difficile-associated infection and disease |
| 02/20/2013 | EP2558485A1 Antigenic polypeptides of trichinella and uses thereof |
| 02/20/2013 | EP2558125A2 Treating disorders associated with il-20 receptor-mediated signaling pathway by blocking il-20 receptor activity |
| 02/20/2013 | EP2558124A1 Polysaccharide compositions and methods of use for the treatment and prevention of disorders associated with progenitor cell mobilization |
| 02/20/2013 | EP2558123A2 Methods and compositions for inhibition of treg cells |
| 02/20/2013 | EP2558122A1 Combination treatment with vegf-c antagonists |
| 02/20/2013 | EP2558121A2 Epha3 antibodies for the treatment of multiple myeloma |
| 02/20/2013 | EP2558120A1 Methods and compositions for intranasal delivery |
| 02/20/2013 | EP2558119A1 Process for treatment of amyotrophic lateral sclerosis, rheumatoid arthritis, tremors/parkinson's disease, multiple sclerosis, non-viral based cancers, alzheimer's disease, muscular dystrophy, attention deficit disorder, attention deficit hyperactivity disorder, complex regional pain syndrome, diabetes, neuropathic pain, spider arthritis, west nile virus, fibromyalgia, shingles, gout, migraine headaches, senile dementia, post polio syndrome, central virus deafness, asthma, chronic pain of unknown origin and hepatitis c |
| 02/20/2013 | EP2558118A1 Cross-protecting vaccine for porcine reproductive and respiratory syndrome virus |
| 02/20/2013 | EP2558117A1 Expression of positive sense single stranded rna virus and uses thereof |
| 02/20/2013 | EP2558116A2 Agent for locally treating cervical dysplasias |
| 02/20/2013 | EP2558112A1 Compositions and methods for treating copd exacerbation |
| 02/20/2013 | EP2558106A1 Methods and compositions for improving implant osseointegration |
| 02/20/2013 | EP2558075A1 Compoisitons comprising polyglutamic acid nanoparticles and polypeptides such as cd40 agonists |
| 02/20/2013 | CN102939538A Diagnostic method for the detection of cells ex vivo |
| 02/20/2013 | CN102939306A Humanized anti cxcr4 antibodies for the treatment of cancer |
| 02/20/2013 | CN102939305A Antibodies to cd122 |
| 02/20/2013 | CN102939303A Tetravalent cd47-antibody constant region fusion protein for use in therapy |
| 02/20/2013 | CN102939111A Process for preparing an immunoglobulin composition |